The global biopharmaceutical landscape is rapidly evolving, driven by innovations targeting complex diseases like organ fibrosis and liver conditions. As companies push the boundaries of medical ...
Hosted on MSN
Gyre Therapeutics Announces Positive Phase 3 Results
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Gyre Therapeutics ( (GYRE)) has provided ...
Hosted on MSN
HC Wainwright & Co. Initiates Coverage of Gyre Therapeutics (GYRE) with Buy Recommendation
Fintel reports that on August 26, 2025, HC Wainwright & Co. initiated coverage of Gyre Therapeutics (NasdaqCM:GYRE) with a Buy recommendation. Analyst Price Forecast Suggests 148.78% Upside As of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback